Search hospitals

>

Missouri

>

Saint Louis

Mercy Hospital Saint Louis

Claim this profile

Saint Louis, Missouri 63141

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Brain Tumor

Conducts research for Breast cancer

511 reported clinical trials

5 medical researchers

Photo of Mercy Hospital Saint Louis in Saint LouisPhoto of Mercy Hospital Saint Louis in Saint LouisPhoto of Mercy Hospital Saint Louis in Saint Louis

Summary

Mercy Hospital Saint Louis is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Brain Tumor, Breast cancer and other specialties. Mercy Hospital Saint Louis is involved with conducting 511 clinical trials across 682 conditions. There are 5 research doctors associated with this hospital, such as Jay W Carlson, Robin D. Hanson, Khaled Awad, and Dan-Arin Silasi, MD.

Area of expertise

1

Cancer

Global Leader

Mercy Hospital Saint Louis has run 81 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Breast Cancer

Global Leader

Mercy Hospital Saint Louis has run 67 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Mercy Hospital Saint Louis

Lung Cancer

Prostate Cancer

Kidney Cancer

Bladder Cancer

Ovarian Cancer

Breast Cancer

Cancer

Esophageal cancer

Bladder Carcinoma

Breast cancer

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Durvalumab

for Lung Cancer

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

Recruiting

2 awards

Phase 3

8 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mercy Hospital Saint Louis?

Where is Mercy Hospital Saint Louis located?

Who should I call to ask about financial aid or insurance network?

What insurance does Mercy Hospital Saint Louis accept?

What awards or recognition has Mercy Hospital Saint Louis received?